Novel Protein Kinase Inhibitors for CHK1 and CHK2
Solution Overview
Problem
Current cancer treatments lack effective inhibitors for tyrosine kinases, particularly CHK1 and CHK2, which are crucial for cell cycle regulation and DNA damage repair, leading to limitations in cancer therapy efficacy.
Innovation Solution
Development of novel protein kinase inhibitor compounds targeting CHK1 and CHK2, as well as other tyrosine kinases, to enhance the sensitivity of cancer cells to DNA damage and complement existing anti-cancer agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (surgery, radiotherapy, chemotherapy) are used, then some cancer cases can be treated, but treatment efficacy is limited and cancer mortality remains high
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with specific molecular structures (Formula I) that target protein kinase enzymes. The compounds feature variable substituents (R1-R6, Y, Z) that can be modified to optimize binding affinity and selectivity for CHK1/CHK2 kinases, thereby improving treatment efficacy while reducing toxicity.
Solution Approach 2:
The patent introduces protein kinase inhibitors as intermediary substances that mediate between the therapeutic goal and the biological target. These compounds act as intermediaries that specifically bind to and inhibit CHK1 and CHK2 kinases, which are involved in DNA damage repair pathways, thereby sensitizing cancer cells to DNA-damaging therapies.
2Reliability
If existing tyrosine kinase inhibitors are used, then some kinase activity is inhibited, but effective inhibitors for CHK1 and CHK2 are still lacking
Solution Approach 1:
The patent achieves universality by designing a compound series (Formula I) that can inhibit multiple kinase targets including CHK1, CHK2, and other tyrosine kinases. The core molecular structure with variable substituents provides a versatile framework that can be optimized for different kinase isoforms and related targets, making the compounds adaptable for treating various cancer types.
Solution Approach 2:
The patent applies segmentation by dividing the kinase inhibitor development into specific structural modules. The Formula I compound contains distinct functional regions (heterocyclic core, substituent groups R1-R6, linkers) that can be independently optimized to achieve selective inhibition of CHK1/CHK2 while maintaining activity against related kinases.
3Reliability
If cancer cells are treated with DNA damage therapy, then cell death can be induced, but drug resistance and tolerance develop
Solution Approach 1:
The patent applies preliminary anti-action by using CHK1/CHK2 inhibitors to pre-block the DNA damage repair pathways before administering DNA-damaging chemotherapy agents. By inhibiting the checkpoint kinases that mediate repair mechanisms in advance, the cancer cells are rendered more susceptible to DNA damage, preventing the development of drug resistance and enhancing therapeutic efficacy.
Data Source
AI summary
Novel compound having the following formula:wherein Y is N, O, or S. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein kinases, especially Checkpoint kinase Chk1/Chk2.